Xian Yu
Appearances
- DateMay 21, 2024BACKGROUND. Several inflammatory and metabolic biomarkers have been associated with hepatocellular carcinoma (HCC) risk in phase I and II biomarker studies but not in longitudinal studies…
Presenter
Baylor College of MedicineSpeakers
Michael E. DeBakey VAMCBaylor College of MedicineUT Southwestern Medical CenterBaylor University Medical Center - DateMay 18, 2024BACKGROUND: Patients with MASLD and diabetes have an increased risk of cirrhosis and hepatocellular cancer (HCC). Recent studies show that glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide, are effective in improving liver inflammation in MASLD…
Presenter
Michael E. DeBakey VAMCSpeakers
The Perelman School of Medicine at the University of PennsylvaniaBaylor College of Medicine
